相关临床试验
59
24 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
10.2%
已完成
18
30.5%
尚未招募
18
30.5%
招募中
13
22.0%
暂停
2
3.4%
终止
2
3.4%
暂无批准数据
- A new blood test can accurately diagnose celiac disease even in patients already following a gluten-free diet, eliminating the need for painful gluten challenges that worsen symptoms. - The test measures interleukin-2 (IL-2) immune response to gluten in blood samples, achieving 90% sensitivity and 97% specificity in detecting celiac disease. - Researchers tested 181 volunteers and found the IL-2 signal strength correlates with symptom severity, potentially predicting how severely patients might react to gluten exposure. - The breakthrough could help diagnose millions of undiagnosed celiac patients worldwide who avoid current testing due to the debilitating diagnostic process.
- Novoviah Pharmaceuticals' NovoleukinTM test platform demonstrated 90% sensitivity and 95% specificity in detecting celiac disease through T cell reactivity measurement in a study of 181 volunteers. - The blood-based diagnostic can detect as few as one gluten-specific T lymphocyte per milliliter of blood, eliminating the need for patients to return to gluten consumption for diagnosis. - The platform successfully identifies celiac disease even in patients following strict gluten-free diets, addressing a major limitation of traditional diagnostic methods. - Results published in Gastroenterology show the test's potential for broader clinical applications in immunotherapy development and monitoring treatment efficacy across multiple immune-mediated diseases.
